Welcome to Peptide Card of AntiTbPdb
| This page displays user query in tabular form. |
MLLKKLLKKM details |
| Primary information | |
|---|---|
| ID | antitb_1247, |
| Name | 24314557 |
| N-Terminal modification | M(LLKK)2M |
| C-Terminal Modification | MLLKKLLKKM |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 10 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis (ATCC No. 14468) |
| Cell Line | MIC = 62.5 mg/L |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Rat red blood cells (rRBCs) |
| In vivo Model | NA |
| Lethal Dose | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Membrane-lytic mechanism |
| Other activities | Cell envelope |
| PMID | None |
| Year of Publication | Antibacterial |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1248, |
| Name | 24314557 |
| N-Terminal modification | M(LLKK)2M |
| C-Terminal Modification | MLLKKLLKKM |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 10 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis (ATCC No. 14468) |
| Cell Line | MIC = 15.6 mg/L |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Rat red blood cells (rRBCs) |
| In vivo Model | NA |
| Lethal Dose | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Membrane-lytic mechanism |
| Other activities | Cell envelope |
| PMID | Rifampicin, shows synergy |
| Year of Publication | Antibacterial |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1249, |
| Name | 24314557 |
| N-Terminal modification | M(LLKK)2M |
| C-Terminal Modification | MLLKKLLKKM |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 10 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis resistant agianst rifampicin |
| Cell Line | MIC = 62.5 mg/L |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Rat red blood cells (rRBCs) |
| In vivo Model | NA |
| Lethal Dose | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Membrane-lytic mechanism |
| Other activities | Cell envelope |
| PMID | None |
| Year of Publication | Antibacterial |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1250, |
| Name | 24314557 |
| N-Terminal modification | M(LLKK)2M |
| C-Terminal Modification | MLLKKLLKKM |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 10 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis resistant agianst rifampicin |
| Cell Line | MIC = 15.6 mg/L |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Rat red blood cells (rRBCs) |
| In vivo Model | NA |
| Lethal Dose | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Membrane-lytic mechanism |
| Other activities | Cell envelope |
| PMID | Rifampicin, shows synergy |
| Year of Publication | Antibacterial |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1251, |
| Name | 24314557 |
| N-Terminal modification | M(LLKK)2M |
| C-Terminal Modification | MLLKKLLKKM |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 10 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium bovis |
| In Vitro/ In vivo | Mycobacterium bovis BCG lux |
| Cell Line | MIC = 15.6 mg/L |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Rat red blood cells (rRBCs) |
| In vivo Model | NA |
| Lethal Dose | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Membrane-lytic mechanism |
| Other activities | Cell envelope |
| PMID | None |
| Year of Publication | Antibacterial |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1252, |
| Name | 24314557 |
| N-Terminal modification | M(LLKK)2M |
| C-Terminal Modification | MLLKKLLKKM |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 10 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium bovis |
| In Vitro/ In vivo | Mycobacterium bovis BCG lux |
| Cell Line | MIC = 3.91 mg/L |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Rat red blood cells (rRBCs) |
| In vivo Model | NA |
| Lethal Dose | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Membrane-lytic mechanism |
| Other activities | Cell envelope |
| PMID | Rifampicin, shows synergy |
| Year of Publication | Antibacterial |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1253, |
| Name | 24314557 |
| N-Terminal modification | M(LLKK)2M |
| C-Terminal Modification | MLLKKLLKKM |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 10 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC = 125 mg/L |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Rat red blood cells (rRBCs) |
| In vivo Model | NA |
| Lethal Dose | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Membrane-lytic mechanism |
| Other activities | Cell envelope |
| PMID | None |
| Year of Publication | Antibacterial |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1254, |
| Name | 24314557 |
| N-Terminal modification | M(LLKK)2M |
| C-Terminal Modification | MLLKKLLKKM |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 10 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC = 7.81 mg/L |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Rat red blood cells (rRBCs) |
| In vivo Model | NA |
| Lethal Dose | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Membrane-lytic mechanism |
| Other activities | Cell envelope |
| PMID | Rifampicin, shows synergy |
| Year of Publication | Antibacterial |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1255, |
| Name | 24314557 |
| N-Terminal modification | M(LLKK)2M |
| C-Terminal Modification | MLLKKLLKKM |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 10 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis CSU87 reistant to rifampicin, isoniazid, ethambutol, streptomycin and kanamycin |
| Cell Line | MIC = 62.5 mg/L |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | Rat red blood cells (rRBCs) |
| In vivo Model | NA |
| Lethal Dose | Very low, i.e. 50% hemolysis concentration (HC50) > 1000 mg/L |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Membrane-lytic mechanism |
| Other activities | Cell envelope |
| PMID | None |
| Year of Publication | Antibacterial |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1620, |
| Name | 26380930 |
| N-Terminal modification | MM |
| C-Terminal Modification | MLLKKLLKKM |
| Chemical Modification | Free |
| Linear/Cyclic | Amidation |
| Length | None |
| Chirality | Linear |
| Nature | 10 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis ATCC14468 |
| Cell Line | MIC = 62.5 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | RAW 264.7 mouse macrophage |
| In vivo Model | NA |
| Lethal Dose | HC50= >500 μg/ml |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1626, |
| Name | 26380930 |
| N-Terminal modification | MM |
| C-Terminal Modification | MLLKKLLKKM |
| Chemical Modification | Free |
| Linear/Cyclic | Amidation |
| Length | None |
| Chirality | Linear |
| Nature | 10 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis ATCC14468 |
| Cell Line | MIC = 15.6 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | RAW 264.7 mouse macrophage |
| In vivo Model | NA |
| Lethal Dose | HC50= >500 μg/ml |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | Peptide + Rifampicin (0.98 μg/ml) |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |